Skip to main content

Table 3 Correlation between smoking and clinical factors

From: The effect of smoking on biological change of recurrent breast cancer

ParametersSmokingp value
No-smoker (n = 36)Smoker (n = 14)
Age at operation (years old)
 ≤ 6019 (52.8%)7 (50.0%)0.863
 > 6017 (47.2%)7 (50.0%)
Tumor size (mm)
 ≤ 21.816 (44.4%)9 (64.3%)0.216
 > 21.820 (55.6%)5 (35.7%)
Lymph node metastasis
 Negative31 (86.1%)12 (85.7%)0.972
 Positive5 (13.9%)2 (14.3%)
Estrogen receptor (ER) of primary tumor
 Negative10 (27.8%)3 (21.4%)0.654
 Positive26 (72.2%)11 (78.6%)
Progesterone receptor (PgR) of primary tumor
 Negative12 (33.3%)3 (21.4%)0.420
 Positive24 (66.7%)11 (78.6%)
HER2 of primary tumor
 Negative35 (97.2%)13 (92.9%)0.490
 Positive1 (2.8%)1 (7.1%)
Ki67 of primary tumor
 ≤ 14%15 (41.7%)4 (28.6%)0.402
 > 14%21 (58.3%)10 (71.4%)
Intrinsic subtype HRBC
 No10 (27.8%)2 (14.3%)0.326
 Yes26 (72.2%)12 (85.7%)
Intrinsic subtype HER2BC
 No35 (97.2%)13 (92.9%)0.490
 Yes1 (2.8%)1 (7.1%)
Intrinsic subtype TNBC
 No27 (75.0%)13 (92.9%)0.163
 Yes9 (25.0%)1 (7.1%)
Chemotherapy after surgery
 No26 (72.2%)11 (78.6%)0.654
 Yes10 (27.8%)3 (21.4%)
Endocrine therapy after surgery
 No11 (30.6%)3 (21.4%)0.529
 Yes25 (69.4%)11 (78.6%)
Radiation therapy after surgery
 No30 (83.3%)9 (64.3%)0.150
 Yes6 (16.7%)5 (35.7%)
Trastuzumab after surgery
 No35 (97.2%)14 (100.0%)0.538
 Yes1 (2.8%)0 (0.0%)
No-treatment after surgery
 No32 (88.9%)12 (85.7%)0.762
 Yes4 (11.1%)2 (14.3%)
Age at recurrence (years old)
 ≤ 6220 (55.6%)6 (42.9%)0.430
 > 6216 (44.4%)8 (57.1%)
Recurrence site biopsied
 Local, regional lymph node31 (86.1%)14 (100.0%)0.108
 Distant metastasis5 (13.9%)0 (0.0%)
Change of ER in recurrence
 Negative conversion2 (5.6%)1 (7.1%)0.836
 The other34 (94.4%)13 (92.9%)
Change of PgR in recurrence
 Negative conversion9 (25.0%)6 (42.9%)0.224
 No change27 (75.0%)8 (57.1%)
Change of HER2 in recurrence
 Positive conversion2 (5.6%)4 (28.6%)0.024
 No change34 (94.4%)10 (71.4%)
Change of intrinsic subtype in recurrent tumor
 No32 (88.9%)13 (92.9%)0.682
 Yes4 (11.1%)1 (7.1%)
Disease free survival
 ≤ 79219 (52.8%)6 (42.9%)0.538
 > 79217 (47.2%)8 (57.1%)
  1. HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PgR progesterone receptor